<DOC>
	<DOCNO>NCT01070186</DOCNO>
	<brief_summary>This study design explore molecular modulatory effect Sunitinib give neoadjuvant set prior radical partial nephrectomy . The study evaluate aforementioned outcomes 30 patient dose 50mg/day 4 week follow surgery 2-4 week follow last dose .</brief_summary>
	<brief_title>Study Sunitinib Subjects With High Risk Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients must least 18 year age Must eligible undergo radical partial nephrectomy Clinical stage T1b , T2 , T3 , T4 and/or N1 disease document abdomen/pelvis CT scan , MRI chest xray CT chest Patients must performance status ECOG scale 01 Patients must pretreatment wbc &gt; 3.0 , granulocyte count &gt; 1000/mm3 , hemoglobin &gt; 8.5 g/dL , platelet count &gt; 100,000/mm3 normal PT PTT Patients must serum creatinine &lt; 2.0 mg/dL Patients must adequate hepatic function serum bilirubin &lt; upper limit normal AST/ALT &lt; 2.5 x upper limit normal Radiographic evidence metastatic disease Prior administration immunotherapy/biotherapy/hormonal radiation renal cell carcinoma Active secondary malignancy ( basal cell carcinoma skin ) Serious , nonhealing wound , ulcer , bone fracture Clinically significant cardiovascular disease , New York Heart Association Grade II great congestive heart failure , serious cardiac arrhythmia require medication Grade II great peripheral vascular disease within 1 year precede Day 0 Any history radiologic evidence central nervous system disease Active infection require parenteral antibiotic time first Sunitinib administration Current recent ( within 10 day precede Day 0 ) use oral parenteral anticoagulant ( except require maintain patency preexisting , permanency indwell IV catheter ) , aspirin Current , recent ( within 4 week precede Day 0 ) , plan participation another experimental drug study Screening clinical laboratory value : ANC &lt; 1000/uL Platelet count &lt; 100,000/uL Total bilirubin &gt; 2.0 mg/dL AST ALT &gt; 2.5 time upper limit normal Serum creatinine &gt; 2.0 mg/dL Hemoglobin &lt; 9 gm/dL ( may transfuse maintain exceed level ) Ongoing cardiac dysrhythmias NCI CTCAE Version 3.0 grade &gt; 2 Prolonged QTc interval baseline EKG Uncontrolled hypertension ( &gt; 150/100 mm Hg despite optimal medical therapy ) Preexisting thyroid abnormality thyroid function maintain normal range medication Patients receive CYP3A4 inducer inhibitor ; patient take grapefruit juice St. John 's Wort study History psychiatric disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Unable take medication mouth</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>nephrectomy</keyword>
	<keyword>T1b</keyword>
	<keyword>T2</keyword>
	<keyword>T3</keyword>
	<keyword>T4</keyword>
	<keyword>N1</keyword>
	<keyword>Kidney Cancer</keyword>
</DOC>